PharmaNutrients awarded CLA use patent

By Clarisse Douaud

- Last updated on GMT

Related tags: Metabolic syndrome, Obesity, Hypertension, Cla

PharmaNutrients has secured a US patent for the use of CLA
for preventing and treating metabolic syndrome, giving
the company exclusive access to burgeoning market potential.

Metabolic syndrome is a common precondition for coronary disease and type 2 diabetes, both of which are key health problems for the US population. CLA, conjugated linoleic acid, is primarily used in dietary supplements for its effects on body composition. The health problem has been getting increasing attention and, as awareness increases, there may be further market opportunities for products supporting the condition. The American Heart Foundation estimates over 50 million people in the US have metabolic syndrome, which is characterized by a group of metabolic risk factors including: abdominal obesity, atherogenic dyslipidemia, high blood pressure and insulin resistance. According to the Center for Disease Control, at least 25 percent of the adult population in US may have metabolic syndrome. CLA is a fatty acid found primarily in milk, beef, and dairy products. It is best known in the food and supplements market for its effects on body composition, but animal studies have also yielded positive results on its potential to reverse the formation of atherosclerotic plaques.​PharmaNutrients has been awarded US patent 7,208,522 for method and composition of CLA for prevention and treatment of metabolic syndrome. "This provides an opportunity to broaden the scope and target CLA to a specific population,"​ PharmaNutrients president Mark Nottoli told NutraIngredients-USA. The Chicago-based company said it has been able to show CLA's role in affecting certain parameters associated with metabolic syndrome. It claims CLA targets abdominal body fat and normalizes blood sugar levels. PharmaNutrients is looking to take the ingredient to different North American distributors to target metabolic syndrome specifically, but it has not finalized plans. The company has also applied for similar patents at the international level. "This patent adds to our CLA intellectual property portfolio and improves our ability to address the important health issues related to diabetes and cardiovascular disease, conditions that, unfortunately, are expanding at an alarming rate,"​ said Nottoli. The company has already obtained CLA use patents related to the reduction of atherosclerotic plaques and weight management. Along with Cognis and Lipid Nutrition, PharmaNutrients was granted a license to the WARF (Wisconsin Alumni Research Foundation) patent for use of CLA (conjugated linoleic acid) in weight management, but in early 2006 PharmaNutrients sold its CLA One business to Lipid Nutrition.

Related news

Show more

Related products

show more

Advanced solution for boosting the gut microbiome

Advanced solution for boosting the gut microbiome

Embria Health Sciences | 30-Nov-2018 | Technical / White Paper

Beyond taking probiotics, consumers understand that boosting the trillions of beneficial bacteria already in their gut can provide health benefits. Prebiotic...

Vegan Weight Management INNOBIO CLA TG

Vegan Weight Management INNOBIO CLA TG

INNOBIO Limited | 19-Nov-2018 | Technical / White Paper

INNOBIO® is announcing the launch of a new vegan CLA TG powder. It can easily be incorporated into a wide range of natural foods and supplements and is...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars